Literature DB >> 27703017

Hospitalized burden and outcomes of coccidioidomycosis: A nationwide analysis, 2005-2012.

Ruihong Luo1, Alan Greenberg2, Christian D Stone3.   

Abstract

The incidence of coccidioidomycosis (CM) infection has increased over the last 20 years. We investigated recent trends of CM-associated hospitalization in the United States. patients with CM-associated hospitalization were identified from the Nationwide Inpatient Sample, 2005-2012. The outcomes of interest were the trend of annual hospitalization, in-hospital mortality, and independent risk factors for mortality. A total of 30,870 hospitalizations with CM (29,584 of adults; 1,286 of children) were identified. Over the 8-year study period, the number of hospitalizations for CM fluctuated but increased overall with successively higher peaks in 2009 and 2011. The annual median length of stay (LOS) shortened from 6 to 7 days in 2005-2010 to 4 days in 2011 and 5 days in 2012. The inflation-adjusted hospital charges were highest in 2006 then trended down by 21% in 2012. The in-hospital mortality declined from the highest level in 2005 (5.2%) to a low in 2010 (1.1%), then increased modestly in 2011 (1.9%) and 2012 (1.5%). Hospitalizations were identified in 46 states, with nearly half in Arizona (49.1%), followed by California (36.8%), Texas (3.3%), and Nevada (1.6%). Logistic regression analysis in adults revealed that in-hospital mortality was associated with age groups 61-70 years and >70 years (OR = 3.3 and 3.5, respectively. Ref: 18-30 years) and Charlson Index ≥1 (OR = 2.0-8.3). In children, males had lower risk for mortality than females (OR = 0.2). This study shows that CM-associated hospitalizations occur widely throughout the United States with an increasing admission trend; however, patient outcomes have improved and the cost of hospitalization has decreased.
© The Author 2016. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Coccidioidomycosis; epidemiology; hospitalization; outcomes; trend

Mesh:

Year:  2017        PMID: 27703017      PMCID: PMC5896874          DOI: 10.1093/mmy/myw087

Source DB:  PubMed          Journal:  Med Mycol        ISSN: 1369-3786            Impact factor:   4.076


  21 in total

Review 1.  Coccidioidomycosis during pregnancy: a review and recommendations for management.

Authors:  Robert S Bercovitch; Antonino Catanzaro; Brian S Schwartz; Demosthenes Pappagianis; D Heather Watts; Neil M Ampel
Journal:  Clin Infect Dis       Date:  2011-08       Impact factor: 9.079

2.  Demonstration of Coccidioides immitis and Coccidioides posadasii DNA in soil samples collected from Dinosaur National Monument, Utah.

Authors:  Suzanne M Johnson; Erin L Carlson; Frederick S Fisher; Demosthenes Pappagianis
Journal:  Med Mycol       Date:  2014-05-20       Impact factor: 4.076

Review 3.  Coccidioidomycosis: a regional disease of national importance. Rethinking approaches for control.

Authors:  J N Galgiani
Journal:  Ann Intern Med       Date:  1999-02-16       Impact factor: 25.391

4.  Posaconazole therapy for chronic refractory coccidioidomycosis.

Authors:  David A Stevens; Adrian Rendon; Veronica Gaona-Flores; Antonino Catanzaro; Gregory M Anstead; Lisa Pedicone; J Richard Graybill
Journal:  Chest       Date:  2007-06-15       Impact factor: 9.410

5.  Valley fever: finding new places for an old disease: Coccidioides immitis found in Washington State soil associated with recent human infection.

Authors:  Anastasia P Litvintseva; Nicola Marsden-Haug; Steven Hurst; Heather Hill; Lalitha Gade; Elizabeth M Driebe; Cindy Ralston; Chandler Roe; Bridget M Barker; Marcia Goldoft; Paul Keim; Ron Wohrle; George R Thompson; David M Engelthaler; Mary E Brandt; Tom Chiller
Journal:  Clin Infect Dis       Date:  2014-08-27       Impact factor: 9.079

Review 6.  Coccidioidomycosis and pregnancy.

Authors:  C M Peterson; K Schuppert; P C Kelly; D Pappagianis
Journal:  Obstet Gynecol Surv       Date:  1993-03       Impact factor: 2.347

Review 7.  The public health impact of coccidioidomycosis in Arizona and California.

Authors:  Richard F Hector; George W Rutherford; Clarisse A Tsang; Laura M Erhart; Orion McCotter; Shoana M Anderson; Kenneth Komatsu; Farzaneh Tabnak; Duc J Vugia; Ying Yang; John N Galgiani
Journal:  Int J Environ Res Public Health       Date:  2011-04-15       Impact factor: 3.390

8.  Coccidioides immitis identified in soil outside of its known range - Washington, 2013.

Authors:  Nicola Marsden-Haug; Heather Hill; Anastasia P Litvintseva; David M Engelthaler; Elizabeth M Driebe; Chandler C Roe; Cindy Ralston; Steven Hurst; Marcia Goldoft; Lalitha Gade; Ron Wohrle; George R Thompson; Mary E Brandt; Tom Chiller
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2014-05-23       Impact factor: 17.586

9.  Coccidioidomycosis-associated hospitalizations, California, USA, 2000-2011.

Authors:  Gail Sondermeyer; Lauren Lee; Debra Gilliss; Farzaneh Tabnak; Duc Vugia
Journal:  Emerg Infect Dis       Date:  2013-10       Impact factor: 6.883

10.  Increase in reported coccidioidomycosis--United States, 1998-2011.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2013-03-29       Impact factor: 17.586

View more
  3 in total

1.  Estimation of Direct Healthcare Costs of Fungal Diseases in the United States.

Authors:  Kaitlin Benedict; Brendan R Jackson; Tom Chiller; Karlyn D Beer
Journal:  Clin Infect Dis       Date:  2019-05-17       Impact factor: 9.079

2.  Epidemiology and Geographic Distribution of Blastomycosis, Histoplasmosis, and Coccidioidomycosis, Ontario, Canada, 1990-2015.

Authors:  Elizabeth M Brown; Lisa R McTaggart; Deirdre Dunn; Elizabeth Pszczolko; Kar George Tsui; Shaun K Morris; Derek Stephens; Julianne V Kus; Susan E Richardson
Journal:  Emerg Infect Dis       Date:  2018-07       Impact factor: 6.883

3.  Coccidioidomycosis Cases at a Regional Referral Center, West Texas, USA, 2013-2019.

Authors:  Christopher Peterson; Victoria Chu; Jessica Lovelace; Mhd Hasan Almekdash; Mark Lacy
Journal:  Emerg Infect Dis       Date:  2022-04       Impact factor: 6.883

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.